Justices today heard oral arguments on the constitutionality of the federal task force that decides which preventive services should be covered. The Trump administration, defending the task force, argued that HHS has appropriate oversight over its members and recommendations. But lawyers for Christian-owned companies challenging the mandate argued that the task force is unconstitutionally imposing coverage requirements because its members aren't politically appointed.
Blue Cross Blue Shield of Massachusetts, the state's largest commercial health insurer, is rolling back its coverage of pricey GLP-1 drugs such as Ozempic and Wegovy for weight loss. The insurer says it would continue covering GLP-1 medication for subscribers with diabetes. Employers that provide their workers with health insurance can also choose to pay extra if they'd like to include GLP-1 for weight loss coverage in their health plans — or opt out entirely.
As Cigna fights off a lawsuit claiming it systematically denied patients coverage, the health insurance giant just paid departing EVP Eric Palmer $10 million in severance.
UnitedHealth revealed in its first-quarter earnings report of 2025 that it faced a $9.8 billion year-over-year increase in revenues so far this year and managed to serve 780,000 new customers. However, UnitedHealth CEO Andrew Witty warned that the company did not meet expectations.
A grand jury indicted Mangione on charges of stalking, murder with a firearm and another gun offense, according to the four-count indictment. Prosecutors say he traveled across state lines to stalk and kill United Healthcare CEO Brian Thompson last December. Federal prosecutors charged Mangione in a complaint that month. The new indictment comes after a grand jury heard evidence and found probable cause to move the case forward. The murder charge is eligible for the death penalty if Mangione is convicted.
When should six drugs count as one? That question is at the heart of an unusual challenge that the pharma company Novo Nordisk is pursuing against the federal government. And the answer could have major ramifications for the Medicare drug price negotiation program, a signature accomplishment of former President Biden that President Trump has also embraced.